M Campone

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]
    Mario Campone
    Service d Oncologie, Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain Cedex
    Bull Cancer 89:275-82. 2002
  2. doi [Tumor resistance to HER2 inhibitors: the drug sedimentation concept]
    Mario Campone
    Centre Rene Gauducheau, Departement d Oncologie Medicale, Boulevard Jacques Monod, 44805 Saint Herblain, Nantes Cedex, France
    Bull Cancer 99:665-72. 2012
  3. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
  4. doi Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
    M Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Nantes Saint Herblain, France
    Ann Oncol 23:610-7. 2012
  5. pmc c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1
    Mario Campone
    Centre de Recherche en Cancérologie Nantes Angers UMR 892 INSERM Université de Nantes, Institut de Recherche Thérapeutique de l Université de Nantes 8 Quai Moncousu BP 7072144007 Nantes Cedex 1 France
    Mol Cancer 10:110. 2011
  6. ncbi [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]
    Mario Campone
    CRLCC, Centre Rene Gauducheau, bd Jacques Monod, 44805 Saint Herblain Nantes
    Bull Cancer 90:851-64. 2003
  7. ncbi [Her2 positive breast cancer: practices]
    Mario Campone
    Institut du cancer Nantes Atlantiques, Centre Rene Gauducheau, Saint Herblain, France
    Bull Cancer 98:154-63. 2011
  8. doi Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
    Mario Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Boulevard Jacques Monod, Nantes Saint Herblain, France
    Crit Rev Oncol Hematol 78:195-205. 2011
  9. ncbi Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors
    M Campone
    CLCC R Gauducheau, St Herblain Nantes, Nantes, France
    Cancer Chemother Pharmacol 59:689-95. 2007
  10. ncbi Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer
    Mario Campone
    Centre Rene Gauducheau, Service Oncologie Medicale, Boulevard Jacques Monod, 44805, Nantes Saint Herblain, France
    Cancer Chemother Pharmacol 63:937-43. 2009

Detail Information

Publications52

  1. ncbi [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]
    Mario Campone
    Service d Oncologie, Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain Cedex
    Bull Cancer 89:275-82. 2002
    ..Weekly administration of paclitaxel which is generally well tolerated increases the therapeutic index (efficacy/safety) resulting from anti-angiogenic and pro-apoptotic effects...
  2. doi [Tumor resistance to HER2 inhibitors: the drug sedimentation concept]
    Mario Campone
    Centre Rene Gauducheau, Departement d Oncologie Medicale, Boulevard Jacques Monod, 44805 Saint Herblain, Nantes Cedex, France
    Bull Cancer 99:665-72. 2012
    ....
  3. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  4. doi Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
    M Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Nantes Saint Herblain, France
    Ann Oncol 23:610-7. 2012
    ..This phase II study evaluated single-agent bosutinib in pretreated patients with locally advanced or metastatic breast cancer...
  5. pmc c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1
    Mario Campone
    Centre de Recherche en Cancérologie Nantes Angers UMR 892 INSERM Université de Nantes, Institut de Recherche Thérapeutique de l Université de Nantes 8 Quai Moncousu BP 7072144007 Nantes Cedex 1 France
    Mol Cancer 10:110. 2011
    ..To address this, we investigated what role anti- and pro-apoptotic Bcl-2 family members, key regulators of cancer cell survival, might play in the viability of HER2 overexpressing breast cancer cells...
  6. ncbi [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]
    Mario Campone
    CRLCC, Centre Rene Gauducheau, bd Jacques Monod, 44805 Saint Herblain Nantes
    Bull Cancer 90:851-64. 2003
    ..In this review, we describe the different pathways implicated in the transduction of signal and the potential target for new agents in breast cancer...
  7. ncbi [Her2 positive breast cancer: practices]
    Mario Campone
    Institut du cancer Nantes Atlantiques, Centre Rene Gauducheau, Saint Herblain, France
    Bull Cancer 98:154-63. 2011
    ..This literature review aims to make the data points on pertinent and useful data for physicians in daily...
  8. doi Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
    Mario Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Boulevard Jacques Monod, Nantes Saint Herblain, France
    Crit Rev Oncol Hematol 78:195-205. 2011
    ....
  9. ncbi Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors
    M Campone
    CLCC R Gauducheau, St Herblain Nantes, Nantes, France
    Cancer Chemother Pharmacol 59:689-95. 2007
    ..This phase I study assessed a split-dose regimen (a 1-h infusion on each of Days 1 to 3, repeated every 3 weeks) to establish the dose limiting toxicities (DLT), to recommended a phase II dose, and to characterize PK/PD...
  10. ncbi Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer
    Mario Campone
    Centre Rene Gauducheau, Service Oncologie Medicale, Boulevard Jacques Monod, 44805, Nantes Saint Herblain, France
    Cancer Chemother Pharmacol 63:937-43. 2009
    ..In an effort to improve patient convenience, we investigated in first-line treatment a regimen alternating i.v. and oral vinorelbine in combination with docetaxel...
  11. ncbi Taxanes in adjuvant breast cancer setting: which standard in Europe?
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44 805 Nantes Cedex Saint Herblain, France
    Crit Rev Oncol Hematol 55:167-75. 2005
    ..remain unanswered, including whether the use of taxanes should be sequential or concomitant, and which population would benefit from such a treatment: patients with hormone-receptor negative disease and/or the HER-2 positive tumors?..
  12. ncbi Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
    M Campone
    Ann Oncol 16:1343-51. 2005
    ..The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients...
  13. ncbi [Cardiac dysfunction induced by trastuzumab]
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 NANTES Cedex
    Bull Cancer 91:166-73. 2004
    ..We discuss in this article the incidence, the physiopathology, the risk factors, the predictive factors and the patient management and on cardiotoxicity of trastuzumab...
  14. doi A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    M Campone
    Centre Rene Gauducheau, Nantes Saint Herblain, France
    Cancer Chemother Pharmacol 69:871-9. 2012
    ....
  15. ncbi Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer
    M Campone
    Centre R Gauducheau, Nantes, France
    Ann Oncol 12:909-18. 2001
    ..CONCLUSION: The recommended doses for phase II studies are docetaxel, 75 mg/m2 (day 1), plus vinorelbine, 20 mg/m2 (days 1 and 5), repeated every three weeks. At these doses, the combination was found to be active and well tolerated...
  16. pmc Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
    M Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Nantes, France
    Br J Cancer 100:315-21. 2009
    ..Everolimus showed an acceptable safety profile at the dose of 30 mg when combined with weekly paclitaxel 80 mg m(-2), warranting further clinical investigation...
  17. ncbi Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer
    R Deporte-Fety
    Centre Rene Gauducheau, Nantes, France
    Cancer Chemother Pharmacol 53:233-8. 2004
    ..To develop a population pharmacokinetic model of vinorelbine administered by short intravenous infusion in metastatic breast cancer patients...
  18. doi Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours
    N Isambert
    Department of Medical Oncology, Centre Georges Francois Leclerc, 1 rue du Pr Marion, 21079 Dijon, France
    Eur J Cancer 46:729-34. 2010
    ..C-1311 is a member of the novel imidazoacridinone family of anticancer agents. This phase 1 trial was designed to investigate the safety, tolerability and preliminary anti-tumour activity of C-1311...
  19. pmc Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
    M Campone
    Centre Rene Gauducheau, 44805 Saint Herblain, France
    Br J Cancer 95:1161-6. 2006
    ..These encouraging phase II results warrant further investigation of this novel agent in combination with other active agents in this setting or in earlier stages of disease...
  20. doi [Chemotherapy for early breast cancer: practices in 2010]
    J S Frenel
    Service d Oncologie Medicale, Centre de Lutte Contre le Cancer René Gauducheau, institut de cancérologie de Nantes Atlantique, Boulevard Jacques Monod, 44805 Nantes Saint Herblain, France
    J Gynecol Obstet Biol Reprod (Paris) 39:F79-84. 2010
    ..The micrometastatic disease appears early in the history of the tumor and chemotherapy aims to eradicate it. In this review, we describe the state of practice regarding adjuvant and neoadjuvant chemotherapy for early breast cancer...
  21. doi Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience
    J S Frenel
    Medical Oncology Department, institut de cancérologie de l Ouest, Centre Rene Gauducheau, 11 Boulevard Jacques Monod, 44800, Saint Herblain, Nantes, France
    J Neurooncol 114:85-91. 2013
    ..6 months, median OS: 9.9 months). Combining two biomarkers, IDH1/2 and 1p/19q codeletion, makes it possible to stratify AO in three groups with very distinct prognostic features...
  22. doi High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
    J Y Pierga
    Department of Medical Oncology, Institut Curie, Paris, France
    Ann Oncol 23:618-24. 2012
    ..Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen and lactate dehydrogenase) variations are needed...
  23. ncbi Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study
    Mario Campone
    Centre Rene Gauducheau, 44805 Nantes St Herblain, France
    Breast 15:601-9. 2006
    ..5 months; median time to progression 8.4 months; and median time to treatment failure 4.8 months. Gemcitabine and epirubicin are well tolerated and active in MBC patients, and the group B regimen warrants further investigation...
  24. ncbi Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen
    Mario Campone
    Service d Oncologie Medicale, Centre de Lutte Contre le Cancer René Gauducheau, Bd J Monod, 44805, Nantes Saint Herblain Cedex, France
    Breast Cancer Res Treat 109:491-501. 2008
    ..The described model adds predictive accuracy to that provided by the well-established Nottingham prognostic index or by our genomic signature alone...
  25. pmc Validation of UBE2C protein as a prognostic marker in node-positive breast cancer
    D Loussouarn
    Service d Anatomie Pathologique B, Hopital G and R Laennec, Bd J Monod, Nantes, Saint Herblain Cedex, France
    Br J Cancer 101:166-73. 2009
    ..The aim of this study was to validate UBE2C protein as a prognostic marker in N+ breast cancer by immunohistochemistry (IHC)...
  26. ncbi Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans
    C Rousseau
    Nuclear Medicine Unit, Rene Gauducheau Cancer Center, Boulevard Monod, 44805 Nantes Saint Herblain, France
    Eur J Nucl Med Mol Imaging 33:785-91. 2006
    ..The aim of this study was to assess changes in FDG uptake in brown fat in patients based on serial PET/CT scans and to compare our results with previous findings...
  27. pmc Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study
    Jean Marc Extra
    Institut Paoli Calmettes, Oncologie Médicale, 232 Boulevard de St Marguerite, 13273 Marseille Cedex 9, France
    Oncologist 15:799-809. 2010
    ..The Hermine study observed the use of trastuzumab for metastatic breast cancer (MBC) in routine practice, including patients who received trastuzumab treatment beyond progression (TBP)...
  28. doi Vinflunine: a new microtubule inhibitor agent
    Jaafar Bennouna
    Centre Rene Gauducheau, Saint Herblain, France
    Clin Cancer Res 14:1625-32. 2008
    ..The efficacy of vinflunine in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen was confirmed by a large phase III trial...
  29. ncbi Vinflunine: a novel antitubulin agent in solid malignancies
    Jaafar Bennouna
    Centre Rene Gauducheau, Saint Herblain, France
    Expert Opin Investig Drugs 14:1259-67. 2005
    ..Clinically significant activity was seen in the Phase II studies for the treatment of bladder, non-small cell lung and breast cancers, thus prompting the initiation of the Phase III trials that are currently ongoing...
  30. ncbi [Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]
    Mario Campone
    Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain, France
    Bull Cancer 90:614-22. 2003
    ..This antibody demonstrated a significant activity in clinical trials. In this review, we discuss the preclinical (mechanisms of action) and clinical data with the combination of trastuzumab and taxanes...
  31. doi A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial
    Pascal Jezequel
    Unité Mixte de Génomique du Cancer, Hopital Laennec, 44805 Nantes, Saint Herblain Cedex, France
    Breast Cancer Res Treat 116:509-20. 2009
    ..The 38-GES represents a robust tool able to type systemic adjuvant treated node-positive patients at high risk of metastatic relapse, and is especially powerful to refine NPI and Adjuvant! classification for those patients...
  32. ncbi Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial
    Pierre Fargeot
    Centre Georges Francois Leclerc, Dijon, France
    J Clin Oncol 22:4622-30. 2004
    ..To assess whether an epirubicin (EPI) -based chemotherapy plus hormonal regimen improves disease-free (DFS) in women older than 65 years, with node-positive, operable breast cancer (BC), relative to tamoxifen (TAM) alone...
  33. ncbi Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial
    Bruno P Coudert
    Department of Oncology, CAC G F Leclerc and IFR 100, Dijon, France
    J Clin Oncol 25:2678-84. 2007
    ..Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation...
  34. ncbi [Targeting ErbB receptors in breast cancer]
    Pierre Fumoleau
    Centre Georges Francois Leclerc, rue du Professeur Marion, 21079 Dijon
    Bull Cancer 94:F147-70. 2007
    ..Combinations between targeted therapies and cytotoxic chemotherapy will certainly allow to take the greatest benefits from these new treatment approaches...
  35. pmc Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme
    P F Cartron
    Centre de Recherche en Cancérologie Nantes Angers, INSERM, U892, Equipe Apoptose et progression tumorale, Equipe labellisée Ligue Nationale Contre le Cancer, CRCNA, Nantes, France
    Cell Death Dis 3:e421. 2012
    ..We also noted that patients with a have high level of phospho-Bad and phospho-Bim displayed a lower OS. Thus, BH3 scoring/profiling could be used as an independent prognostic factor in GBM when globally analyzed...
  36. doi [Prognostic and predictive factors for gliomas in adults]
    J S Frenel
    Service d Oncologie Medicale, institut de cancérologie de Nantes Atlantique, CRLCC Rene Gauducheau, Boulevard Jacques Monod, Saint Herblain, 44805 NANTES Cedex, France
    Bull Cancer 96:357-67. 2009
    ..This status may have important implications for the design of future trials...
  37. doi Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
    M Arnedos
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:2293-9. 2012
    ....
  38. ncbi Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours
    J Bennouna
    Centre Rene Gauducheau, Nantes Saint Herblain, France
    Ann Oncol 14:630-7. 2003
    ..In human tumour xenografts, vinflunine showed definite antitumour activity in seven out of 11 tumours tested compared with three out of 11 for vinorelbine...
  39. ncbi Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
    Mario Campone
    Centre Rene Gauducheau, Nantes, France
    Cancer Chemother Pharmacol 60:523-33. 2007
    ..To determine the maximum tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compound, in advanced solid tumor patients...
  40. ncbi Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
    S Delaloge
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 25:1152-8. 2014
    ..This phase II trial evaluated the efficacy and safety of trabectedin in BRCA1/2 germline mutation carriers with pretreated metastatic breast cancer (MBC)...
  41. ncbi Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors
    Gabriel Ricolleau
    Département de Biologie Oncologique, Centre de Lutte Contre le Cancer René Gauducheau, Nantes, Saint Herblain Cedex, France
    Proteomics 6:1963-75. 2006
    ..SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer...
  42. pmc Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
    H Bonnefoi
    Department of Medical Oncology, Institut Bergonié Comprehensive Cancer Centre, Universite de Bordeaux, INSERM U916, Bordeaux, France
    Ann Oncol 25:1128-36. 2014
    ..Within a phase III neoadjuvant chemotherapy trial, we sought to determine whether the prognostic implications of pCR, TP53 status and treatment arm (taxane versus non-taxane) differed between intrinsic subtypes...
  43. pmc Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas
    D Loussouarn
    Department of Pathology, University Hospital of Nantes, Nantes, France
    Br J Cancer 98:1993-8. 2008
    ..Using multivariate Cox analysis, loss of epithelial syndecan-1 expression was the only prognostic indicator (P<0.001). We concluded that the loss of syndecan-1 epithelial expression was of strong prognostic value in breast carcinomas...
  44. ncbi Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein
    M Campone
    INSERM U419, Nantes, France
    Leukemia 15:1377-87. 2001
    ..Our data show that acquired chemoresistance could involve a parallel induction of P-gp and an impairment of the apoptotic pathway...
  45. ncbi Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy
    Béatrice Clémenceau
    INSERM U601, Nantes Cedex, France
    J Immunother 29:53-60. 2006
    ..Consequently, adoptive transfer of lymphocytes mediating ADCC can be considered using this protocol to test its benefit in patients under Herceptin treatment...
  46. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  47. ncbi Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
    Caroline Rousseau
    Nuclear Medicine Unit, Rene Gauducheau Cancer Center, Saint Herblain, France
    J Clin Oncol 24:5366-72. 2006
    ..This study aimed to assess prospectively the efficacy of sequential [18F]fluorodeoxyglucose positron emission tomography (FDG PET) to evaluate early response to neoadjuvant chemotherapy in stage II and III breast cancer patients...
  48. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
    ..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...
  49. ncbi Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
    Henri Roche
    Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
    J Clin Oncol 24:5664-71. 2006
    ....
  50. ncbi Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    Eva S Thomas
    M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:5210-7. 2007
    ..This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer...
  51. ncbi Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study
    Delphine Loussouarn
    Department of Pathology, University Hospital of Nantes, France
    Hum Pathol 37:415-21. 2006
    ..Some meningiomas exhibit HER2 protein overexpression in part induced by gene amplification. However, only HER2 overexpression could represent an independent prognostic factor in meningiomas...
  52. ncbi [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?]
    Olivier Couturier
    INSERM U601, quai Moncousu, Nantes et Service de médecine nucléaire, 5, Place Alexis Ricordeau, Hotel Dieu, 44093, Nantes Cedex
    Bull Cancer 92:789-98. 2005
    ..Until these studies are completed, FLT should be considered as a promising tracer, but remaining at an experimental stage of its development...